GLP-1s feature in second batch of national priority vouchers
The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 agonists for weight-loss from Eli Lilly and Novo Nordisk and drugs for cancer and rare diseases. The scheme – first announced …